Gilead­'s chief strat­e­gy ex­ec gets a big pro­mo­tion af­ter or­ches­trat­ing multi­bil­lion-dol­lar deals

Af­ter gain­ing cred­it as the ar­chi­tect of Gilead’s $12 bil­lion Kite buy­out as well as the re­cent $5 bil­lion part­ner­ship with Gala­pa­gos, chief strat­e­gy of­fi­cer An­drew Dick­in­son is be­ing pro­mot­ed to the pres­ti­gious CFO post at the big biotech. And new CEO Daniel O’Day says the lat­est move com­pletes his makeover of the top team.

Dick­in­son will re­main in charge of strat­e­gy in his new post.

A 3-year vet­er­an at Gilead, Dick­in­son joined the bell­wether biotech af­ter a lengthy stint at Lazard Frères & Co, where he was glob­al co-head of health­care in­vest­ing. Be­fore that, iron­i­cal­ly enough, he had been at Myo­gen, which was bought out by Gilead in 2006. Now he’ll be pri­mar­i­ly re­spon­si­ble for build­ing con­fi­dence in the num­bers at a com­pa­ny that has a strong foun­da­tion in HIV, a dis­ap­pear­ing fran­chise in hep C and a CAR-T sub­sidiary in Kite that has a long way to go in es­tab­lish­ing a new busi­ness.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER